Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Plan your meal structure and timing
BPC-157 Vial Synthetic research peptide supplied as lyophilised powder for laboratory investigation
[1] [2] It is currently being evaluated in Phase 3 clinical trials for the management of obesity and type 2 diabetes
However, the higher baseline HbA1c in the PIONEER 3 trial (8.31% in PIONEER 3 compared with 7.96% in PIONEER 4) was felt to be more aligned with target population in Portugal, and to correlate with the large reductions in HbA1c observed in the NMA with oral semaglutide 14 mg, and therefore the PIONEER 3 data were used in the base case analysis
For cagrilintide , the most significant trial programme involves its combination with semaglutide (CagriSema), investigated in the REDEFINE trial series
The PMC review of Contrave trials shows weight loss ranged from 3.7% to 8.1% depending on the study protocol
